Yossi Rosman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Yossi Rosman has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
Ronit Confino-Cohen
Meir Medical Center
11 shared publicationsIdit Lachover-Roth
Meir Medical Center
9 shared publicationsKeren Meir-Shafrir
Allergy and Clinical Immunology Unit, Meir Medical Center, Kfar Saba, Israel
8 shared publicationsAnat Cohen-Engler
Allergy and Clinical Immunology Unit, Meir Medical Center, Kfar Saba, Israel
6 shared publicationsMichael Kassirer
Israel Defense Forces Medical Corps, Ramat Gan, Israel
4 shared publicationsShai Shrot
Israel Defense Forces, Medical Corps, Tel Hashomer, Israel
4 shared publications
Latest Publications
- Open Access
- 15 May 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (10) , 3476
Can Beta-Lactam Allergy De-Labeling Strategies Safely Empower Geriatric Care?
Background: Drug allergies constitute a significant health concern among the elderly, with beta-lactam (BL) antibiotics among the most frequently implicated agents. Nevertheless, data regarding the safety and efficacy of BL allergy de-labeling in this population remain scarce. This study aimed to evaluate the safety and efficacy of BL allergy assessment in a cohort of geriatric patients carrying BL allergy labels. Methods: We conducted a retrospective study, including patients aged >65 years who were referred for BL allergy evaluation at the Allergy Unit of Meir Medical Center. Patients underwent comprehensive anamnesis, skin testing, and, when indicated, oral challenge. Those successfully de-labeled were followed longitudinally to assess subsequent BL use and clinical outcomes. Results: Between 2009 and 2019, 166 elderly patients with suspected BL allergies were evaluated. A BL allergy was ruled out in 145 patients (87.3%). Sixteen patients (9.6%) were diagnosed with immediate-type hypersensitivity, 2.4% of patients had severe delayed-type hypersensitivity reactions, and one patient (0.6%) had a benign rash. The evaluation process was safe, with no severe reactions occurring during oral challenges, and no patient required hospitalization or epinephrine administration. A long-term follow up was available for 106 patients; among them, 38 (35.8%) received subsequent treatment with the previously suspected BL agent, without any reports of immediate or severe delayed reactions. Conclusions: Beta-lactam allergy de-labeling is safe and effective in the elderly and supports the critical role of allergy evaluation in this population. Enhanced awareness and implementation of de-labeling protocols in geriatric patients are warranted.
- 15 May 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (10) , 3476
Open AccessCan Beta-Lactam Allergy De-Labeling Strategies Safely Empower Geriatric Care?
Background: Drug allergies constitute a significant health concern among the elderly, with beta-lactam (BL) antibiotics among the most frequently implicated agents. Nevertheless, data regarding the safety and efficacy of BL allergy de-labeling in this population remain scarce. This study aimed to evaluate the safety and efficacy of BL allergy assessment in a cohort of geriatric patients carrying BL allergy labels. Methods: We conducted a retrospective study, including patients aged >65 years who were referred for BL allergy evaluation at the Allergy Unit of Meir Medical Center. Patients underwent comprehensive anamnesis, skin testing, and, when indicated, oral challenge. Those successfully de-labeled were followed longitudinally to assess subsequent BL use and clinical outcomes. Results: Between 2009 and 2019, 166 elderly patients with suspected BL allergies were evaluated. A BL allergy was ruled out in 145 patients (87.3%). Sixteen patients (9.6%) were diagnosed with immediate-type hypersensitivity, 2.4% of patients had severe delayed-type hypersensitivity reactions, and one patient (0.6%) had a benign rash. The evaluation process was safe, with no severe reactions occurring during oral challenges, and no patient required hospitalization or epinephrine administration. A long-term follow up was available for 106 patients; among them, 38 (35.8%) received subsequent treatment with the previously suspected BL agent, without any reports of immediate or severe delayed reactions. Conclusions: Beta-lactam allergy de-labeling is safe and effective in the elderly and supports the critical role of allergy evaluation in this population. Enhanced awareness and implementation of de-labeling protocols in geriatric patients are warranted.
- Open Access
- 2 September 2024
- Published by Springer Nature in Research Square
Empowering Geriatric care: Safe Beta-Lactam Allergy De-labeling Strategies
Purpose: Drug allergies represent a significant health concern among the elderly, with beta-lactam (BL) antibiotics being one of the most implicated agents. There remains a paucity of data on the safety and efficacy of BL allergy de-labelling in this population. We aimed to investigate the safety and efficacy of BL allergy evaluation in a cohort of geriatric patients bearing BL allergy labels. Methods: A retrospective study, including patients aged > 65 years referred for allergy evaluation at the Allergy Unit of the Meir Hospital. Patients suspected to have BL allergy underwent a comprehensive anamnesis, skin testing, and oral challenge. Patients successfully de-labelled were subject to long-term follow-up to monitor BL use and outcomes. Results: Over the course of 2009 to 2019, 166 elders with suspected BL allergies were evaluated. Ultimately, 145 (87.3%) patients had their BL allergies ruled out. Sixteen (9.6%) were diagnosed with IgE-mediated allergies, 4 (2.4%) with severe delayed-type hypersensitivity, and 1 (0.6%) with a benign rash. The evaluation process was safe, with no occurrences of severe reactions during oral challenges, and none of the patients required hospital admission or adrenaline treatment. 106 patients were available for long-term follow-up. Of these, 38 patients (35.8%) were subsequently treated with the previously suspected culprit drug. None reported immediate reactions or severe delayed hypersensitivity following exposure. Conclusion: De-labelling of BL allergies is safe and effective in elders, underscoring the importance of this procedure. There is need to heighten awareness regarding allergic workups in geriatric populations bearing BL allergy labels.
- 2 September 2024
- Published by Springer Nature in Research Square
Open AccessEmpowering Geriatric care: Safe Beta-Lactam Allergy De-labeling Strategies
Purpose: Drug allergies represent a significant health concern among the elderly, with beta-lactam (BL) antibiotics being one of the most implicated agents. There remains a paucity of data on the safety and efficacy of BL allergy de-labelling in this population. We aimed to investigate the safety and efficacy of BL allergy evaluation in a cohort of geriatric patients bearing BL allergy labels. Methods: A retrospective study, including patients aged > 65 years referred for allergy evaluation at the Allergy Unit of the Meir Hospital. Patients suspected to have BL allergy underwent a comprehensive anamnesis, skin testing, and oral challenge. Patients successfully de-labelled were subject to long-term follow-up to monitor BL use and outcomes. Results: Over the course of 2009 to 2019, 166 elders with suspected BL allergies were evaluated. Ultimately, 145 (87.3%) patients had their BL allergies ruled out. Sixteen (9.6%) were diagnosed with IgE-mediated allergies, 4 (2.4%) with severe delayed-type hypersensitivity, and 1 (0.6%) with a benign rash. The evaluation process was safe, with no occurrences of severe reactions during oral challenges, and none of the patients required hospital admission or adrenaline treatment. 106 patients were available for long-term follow-up. Of these, 38 patients (35.8%) were subsequently treated with the previously suspected culprit drug. None reported immediate reactions or severe delayed hypersensitivity following exposure. Conclusion: De-labelling of BL allergies is safe and effective in elders, underscoring the importance of this procedure. There is need to heighten awareness regarding allergic workups in geriatric populations bearing BL allergy labels.
- 14 January 2023
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 11 (4) , 1290-1294
Chronic Urticaria in Elderly—New Insights
- 14 January 2023
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 11 (4) , 1290-1294
Chronic Urticaria in Elderly—New Insights
- Open Access
- 17 November 2022
- Published by Elsevier in World Allergy Organization Journal
- Vol. 15 (11) , 100712
The effect of asthma specialist intervention on asthma control among adults
- 17 November 2022
- Published by Elsevier in World Allergy Organization Journal
- Vol. 15 (11) , 100712
Open AccessThe effect of asthma specialist intervention on asthma control among adults
- Open Access
Humoral Response to Hepatitis B and COVID-19 Vaccine among Maintenance Hemodialysis Patients
Maintenance hemodialysis (MHD) patients have impaired immunological responses to pathogens and vaccines. In this study, we compared the humoral response to HBV and COVID-19 vaccines in a cohort of MHD patients. Demographic and clinical characteristics of vaccine responders and non-responders were also compared, and the association between the humoral responses to both vaccines was evaluated. The cohort included 94 MHD patients who were vaccinated at least once for HBV and twice for COVID-19. Among the 94 patients, 28 (29.8%) did not develop protective titers to HBV. Hypertension, coronary heart disease, and heart failure were more common in non-responders. Among MHD patients, 85% had positive IgG anti-spike SARS-CoV-2 levels 6 months after two doses of BNT162b2 (Pfizer/Biotech) vaccine. Age and immunosuppressive therapy were the main predictors of humoral response to COVID-19 vaccine. We did not find any association between non-responders to HBV and non-responders to COVID-19 vaccine. There was no difference in IgG anti-spike titers between HBV responders and non-responders (505 ± 644 vs. 504 ± 781, p = 0.9) Our results suggest that reduced humoral response to hepatitis B is not associated with reduced response to COVID-19 vaccine. Different risk-factors were associated with poor immune response to HBV and to COVID-19 vaccines.
Open AccessHumoral Response to Hepatitis B and COVID-19 Vaccine among Maintenance Hemodialysis Patients
Maintenance hemodialysis (MHD) patients have impaired immunological responses to pathogens and vaccines. In this study, we compared the humoral response to HBV and COVID-19 vaccines in a cohort of MHD patients. Demographic and clinical characteristics of vaccine responders and non-responders were also compared, and the association between the humoral responses to both vaccines was evaluated. The cohort included 94 MHD patients who were vaccinated at least once for HBV and twice for COVID-19. Among the 94 patients, 28 (29.8%) did not develop protective titers to HBV. Hypertension, coronary heart disease, and heart failure were more common in non-responders. Among MHD patients, 85% had positive IgG anti-spike SARS-CoV-2 levels 6 months after two doses of BNT162b2 (Pfizer/Biotech) vaccine. Age and immunosuppressive therapy were the main predictors of humoral response to COVID-19 vaccine. We did not find any association between non-responders to HBV and non-responders to COVID-19 vaccine. There was no difference in IgG anti-spike titers between HBV responders and non-responders (505 ± 644 vs. 504 ± 781, p = 0.9) Our results suggest that reduced humoral response to hepatitis B is not associated with reduced response to COVID-19 vaccine. Different risk-factors were associated with poor immune response to HBV and to COVID-19 vaccines.
- Open Access
- 1 October 2022
- Published by Elsevier in World Allergy Organization Journal
- Vol. 15 (10) , 100696
Changes in peripheral blood eosinophils may predict colorectal cancer – A retrospective study
- 1 October 2022
- Published by Elsevier in World Allergy Organization Journal
- Vol. 15 (10) , 100696
Open AccessChanges in peripheral blood eosinophils may predict colorectal cancer – A retrospective study
- Open Access
- 1 November 2021
- Published by Taylor & Francis in Journal of Asthma and Allergy
- Vol. ume 14, 1367-1373
Childhood Asthma – The Effect of Asthma Specialist Intervention on Asthma Control: A Retrospective Review
Background: Childhood asthma is the most common chronic disease throughout the western world. Improving asthma control is a leading health management goal. Purpose: To evaluate the effect of an intervention by a visit to an asthma specialist on asthma control in children. Materials and Methods: This retrospective study was conducted using the electronic database of Maccabi Health Services. All members ages 5– 16 with an asthma diagnosis during 2000– 2016, and at least one visit to a specialist were included. Asthma outcomes during the 2 years before and after the visit to the asthma specialist were compared. Results: A total of 37,066 children were diagnosed with asthma. Among them, 13,533 (36.5%) had at least one visit to an asthma specialist and were included. Children with asthma visited their primary care physician more often in the period before the specialist visit (4.4± 4.4 vs 3.16± 3.9 visits, respectively; p< 0.01). After visiting a specialist, average number of visits to emergency departments (0.52± 1.3 vs 0.45± 1), all cause hospitalizations (0.13± 0.45 vs 0.08± 0.4) and hospitalizations due to asthma exacerbations (0.08± 0.345 vs 0.05± 0.3) decreased (p< 0.01 for all comparisons). Prescription of short-acting beta agonists decreased (2.85± 3.6 vs 2.2 ± 3.7, p< 0.01) and inhaled steroid prescriptions increased (1.9± 2.9 vs 2.7± 3.7, p< 0.01), respectively, after the intervention. A substantial reduction in the prescription of corticosteroids (0.81± 1.9 vs 0.43± 1.4, p< 0.01) after specialist visit was also noted. Conclusion: We found significant positive outcomes after a single consultation with an asthma specialist. Referring pediatric asthma patients to an asthma specialist should be one of the goals of an asthma management plan.
- 1 November 2021
- Published by Taylor & Francis in Journal of Asthma and Allergy
- Vol. ume 14, 1367-1373
Open AccessChildhood Asthma – The Effect of Asthma Specialist Intervention on Asthma Control: A Retrospective Review
Background: Childhood asthma is the most common chronic disease throughout the western world. Improving asthma control is a leading health management goal. Purpose: To evaluate the effect of an intervention by a visit to an asthma specialist on asthma control in children. Materials and Methods: This retrospective study was conducted using the electronic database of Maccabi Health Services. All members ages 5– 16 with an asthma diagnosis during 2000– 2016, and at least one visit to a specialist were included. Asthma outcomes during the 2 years before and after the visit to the asthma specialist were compared. Results: A total of 37,066 children were diagnosed with asthma. Among them, 13,533 (36.5%) had at least one visit to an asthma specialist and were included. Children with asthma visited their primary care physician more often in the period before the specialist visit (4.4± 4.4 vs 3.16± 3.9 visits, respectively; p< 0.01). After visiting a specialist, average number of visits to emergency departments (0.52± 1.3 vs 0.45± 1), all cause hospitalizations (0.13± 0.45 vs 0.08± 0.4) and hospitalizations due to asthma exacerbations (0.08± 0.345 vs 0.05± 0.3) decreased (p< 0.01 for all comparisons). Prescription of short-acting beta agonists decreased (2.85± 3.6 vs 2.2 ± 3.7, p< 0.01) and inhaled steroid prescriptions increased (1.9± 2.9 vs 2.7± 3.7, p< 0.01), respectively, after the intervention. A substantial reduction in the prescription of corticosteroids (0.81± 1.9 vs 0.43± 1.4, p< 0.01) after specialist visit was also noted. Conclusion: We found significant positive outcomes after a single consultation with an asthma specialist. Referring pediatric asthma patients to an asthma specialist should be one of the goals of an asthma management plan.
- 2 July 2021
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 9 (9) , 3487-3489
Safety of BNT162b2 mRNA COVID-19 vaccine in patients with mast cell disorders
- 2 July 2021
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 9 (9) , 3487-3489
Safety of BNT162b2 mRNA COVID-19 vaccine in patients with mast cell disorders
- Open Access
- 1 February 2021
- Published by Elsevier in World Allergy Organization Journal
- Vol. 14 (2) , 100506
Clinical history in suspected cases of immediate allergy to beta-lactam
- 1 February 2021
- Published by Elsevier in World Allergy Organization Journal
- Vol. 14 (2) , 100506
Open AccessClinical history in suspected cases of immediate allergy to beta-lactam
- 1 July 2019
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 81 (1) , 129-135
Characterization of chronic urticaria and associated conditions in a large population of adolescents
- 1 July 2019
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 81 (1) , 129-135
Characterization of chronic urticaria and associated conditions in a large population of adolescents